Next |
home / stock / grtx / grtx message board
Subject | By | Source | When |
---|---|---|---|
I am a holder of a lot of | turning stone | investorshub | 04/23/2023 9:46:50 PM |
march 10/23 PR. | 57_2001 | investorshub | 03/10/2023 1:14:59 PM |
march 8/23 PR. | 57_2001 | investorshub | 03/08/2023 5:03:18 PM |
upgrade B of A . from 2 | 57_2001 | investorshub | 02/17/2023 10:08:56 PM |
corporate page update. | 57_2001 | investorshub | 02/15/2023 2:41:56 PM |
prs | 57_2001 | investorshub | 02/15/2023 2:23:13 PM |
feb 13. new 13g. | 57_2001 | investorshub | 02/13/2023 8:51:45 PM |
the company should have a reply | 57_2001 | investorshub | 02/13/2023 6:52:40 PM |
for more | 57_2001 | investorshub | 02/10/2023 5:18:37 PM |
sc13/d info. | 57_2001 | investorshub | 02/10/2023 3:54:43 PM |
Compliance complete. 8-k 1/25/23 | 57_2001 | investorshub | 01/27/2023 12:08:03 AM |
the FDA has sixty days to | 57_2001 | investorshub | 01/15/2023 3:38:01 PM |
NDA | 57_2001 | investorshub | 12/12/2022 2:55:26 PM |
third gt. results. | 57_2001 | investorshub | 11/09/2022 2:29:23 PM |
10/26 new PR. | 57_2001 | investorshub | 10/26/2022 6:10:59 PM |
info. asco | 57_2001 | investorshub | 05/26/2022 10:20:58 PM |
rucosopasem is in early testing, | 57_2001 | investorshub | 05/18/2022 1:19:36 PM |
PR info. | 57_2001 | investorshub | 05/16/2022 12:58:05 PM |
asco info. | 57_2001 | investorshub | 04/27/2022 3:57:41 PM |
info. | 57_2001 | investorshub | 04/17/2022 4:50:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Galera Therapeutics Inc. Company Name:
GRTX Stock Symbol:
NYSE Market:
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results fo...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the ...